CD79B Antibody (ZL9-3): sc-13530

CD79B Antibody (ZL9-3) is a mouse monoclonal IgG1 antibody that detects CD79B in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). CD79B, also known as B29, plays a crucial role in the B cell antigen receptor (BCR) complex, where CD79B partners with CD79A to facilitate the signaling necessary for B cell activation and development. CD79B initiates downstream signaling cascades through its immunoreceptor tyrosine-based activation motif (ITAM), which is located in its cytoplasmic tail. This motif is essential for the recruitment and activation of tyrosine kinases, leading to a series of phosphorylation events that ultimately result in B cell proliferation and differentiation. Given its pivotal role in the immune response, CD79B is a significant target for research into B cell-related diseases, including various forms of lymphoma and autoimmune disorders. Anti-CD79B antibody (ZL9-3) is an invaluable tool for researchers aiming to explore the complexities of B cell signaling and its implications in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD79B Antibody (ZL9-3) References:

1. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma.  |  Dornan, D., et al. 2009. Blood. 114: 2721-9. PMID: 19633198
2. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.  |  Palanca-Wessels, MC., et al. 2015. Lancet Oncol. 16: 704-15. PMID: 25925619
3. MYD88L265P and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy.  |  Chen, R., et al. 2022. Ther Adv Hematol. 13: 20406207211072839. PMID: 35126963
4. The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-analysis and Systematic Literature Review.  |  Xu, PP., et al. 2022. Clin Lymphoma Myeloma Leuk. 22: e1051-e1058.e1. PMID: 36182550
5. Anti-CD79b/CD3 bispecific antibody combined with CAR19-T cells for B-cell lymphoma treatment.  |  Zheng, WW., et al. 2023. Cancer Immunol Immunother. 72: 3739-3753. PMID: 37707586
6. Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas.  |  Chu, F., et al. 2023. J Immunother Cancer. 11: PMID: 38007239
7. Human CD79b+ neutrophils in the blood are associated with early-stage melanoma.  |  Meyer, MA., et al. 2023. Front Immunol. 14: 1224045. PMID: 38022639
8. An inducible Cd79b mutation confers ibrutinib sensitivity in mouse models of Myd88-driven diffuse large B-cell lymphoma.  |  Flümann, R., et al. 2024. Blood Adv. 8: 1063-1074. PMID: 38060829
9. B-Cell Receptor Signaling and Beyond: The Role of Igα (CD79a)/Igβ (CD79b) in Normal and Malignant B Cells.  |  Tkachenko, A., et al. 2023. Int J Mol Sci. 25: PMID: 38203179
10. A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88mut /CD79Bmut diffuse large B-cell lymphoma.  |  Deng, T., et al. 2024. Cancer Med. 13: e7005. PMID: 38457222

The preferred CD79B antibody is CD79B Antibody (B29/123): sc-53210.